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The objective of this study was to identify prognostic factors for survival in patients with advanced oesophageal cancer, who are
treated with cisplatin-based combination chemotherapy. We analysed the baseline characteristics of 350 patients who were treated
in six consecutive prospective trials with one of the following regimens: cisplatin/etoposide, cisplatin/etoposide/5-fluorouracil,
cisplatin/paclitaxel (weekly) and cisplatin/paclitaxel (biweekly). Predictive factors in univariate analyses were further evaluated using
multivariate analysis (Cox regression). The median survival of all patients was 9 months. The 1, 2 and 5-year survival rates were 33, 12
and 4%, respectively. The main prognostic factors were found to be WHO performance status (0 or 1 vs 2), lactate dehydrogenase
(normal vs elevated), extent of disease (limited disease defined as locoregional irresectable disease or lymph node metastases
confined to either the supraclavicular or celiac region vs extensively disseminated disease) in addition to the type of treatment
(weekly or biweekly cisplatin/paclitaxel regimen vs 4-weekly cisplatin/etoposide with or without 5-fluorouracil). Although weight loss,
liver metastases and alkaline phosphatase were significant prognostic factors in univariate analyses, these factors lost their significance
in multivariate analyses. The median survival for patients without any risk factors was 12 months, compared to only 4 months in
patients with WHO 2 plus elevated LDH and extensive disease. The performance status, extent of disease, LDH and the addition of
paclitaxel to cisplatin are independent prognostic factors in patients with advanced oesophageal cancer, who are treated with
cisplatin-based combination chemotherapy.
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The outlook for patients with oesophageal cancer is poor. Many
patients who present with symptoms of oesophageal obstruction
already have locally advanced or metastatic disease. The 5-year
survival rate following surgery in patients thought to have localised
disease is only 20% (Muller et al, 1990; Millikan et al, 1995). Most
patients with oesophageal cancer need palliative treatment for local
recurrence and/or metastases at some stage of the disease.
Palliative surgery to relieve dysphagia carries a high morbidity
and the median survival following surgery in these patients is 5–8
months. Therefore, palliative surgery has been replaced by less
aggressive treatments. Intraluminal radiotherapy, intubation with
self-expanding metal stents and laser therapy are all effective in
palliation of dysphagia, and are associated with less morbidity than
surgery (Siersema et al, 1998). The median survival after these
types of noninvasive palliative treatment is only 3–6 months,
comparable to the survival of patients with untreated advanced
oesophageal cancer (Low and Pagliero, 1992; Knyrim et al, 1993).
Despite the palliation of dysphagia, the quality of life rapidly
deteriorates in most patients, due to disease-related symptoms
such as pain, fatigue, appetite loss and constipation (Blazeby et al,
1995, 2000).
Chemotherapy may offer palliation and/or prolongation of
survival in patients with advanced oesophageal cancer. Combina-
tion chemotherapy, usually cisplatin based, has been evaluated
in several phase II studies and response rates of 25–40% have
been reported (Enzinger et al, 1999). However, the impact
of chemotherapy on the survival and quality of life is unknown
due to a lack of randomised phase III studies comparing
chemotherapy to supportive care alone. Furthermore, it is unclear
which patients will benefit from palliative chemotherapy and
whether potential benefits outweigh the toxicities caused by
such treatment. In one of the few randomised trials that have
been performed in patients with metastatic disease, the combina-
tion of cisplatin and 5-fluorouracil was more effective
than cisplatin alone, but at the cost of severe toxicity (Bleiberg
et al, 1997). In recent phase II studies, response rates
after treatment with cisplatin combined with either paclitaxel
(Ilson et al, 2000) or irinotecan (Ilson et al, 1999) seemed to
be higher than after treatment with cisplatin and 5-fluoroura-
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lcil; randomised studies, however, have not been performed thus
far.
The outcome of chemotherapy and the prognosis of patients
with oesophageal cancer most probably depend on both patient
and disease characteristics. Knowledge of these factors may be
useful for patient and treatment selection. In this study, we
analysed a number of putative prognostic factors in patients who
were treated in six consecutive prospective clinical trials with
cisplatin-based chemotherapy.
PATIENTS AND METHODS
Patient population
Patients were entered in six consecutive prospective studies with
cisplatin-based chemotherapy. The details of these studies are
listed in Table 1. All patients had either squamous cell carcinoma
or adenocarcinoma of the oesophagus or oesophago-gastric
junction. Eligibility criteria for all these trials included histologi-
cally proven metastatic or unresectable oesophageal cancer, a life
expectancy of more than 12 weeks; age X18 years; WHO
performance status 0–2; informed consent; adequate haematolo-
gical, renal and hepatic functions defined as: granulocytes
X1.5 10
9l
 1, platelets X100 10
9l
 1, total bilirubin p1.5 
upper normal limit and creatinine p120mmoll
 1. Prior radio-
therapy was allowed if not involving more than 30% of the bone
marrow. Prior chemotherapy was not allowed. Patients had no
history of other malignancies except for nonmelanomatous skin
cancer or a cured malignancy more than 5 years prior to
enrollment. Further exclusion criteria were: pre-existing neuro-
toxicity greater than common toxicity criteria (CTC) grade 1,
active infection or other serious underlying medical condition
which would impair the ability of the patient to receive the planned
treatment, inadequate calorie and fluid intake and mental
disorders not permitting adequate informed consent.
Pretreatment evaluations consisted of a complete medical
history, physical examination, complete blood cell count and
serum biochemistry, computerised tomography (CT) scan of the
chest and upper abdomen and ultrasonography of the supracla-
vicular nodes when appropriate. Patients with the primary tumour
in situ were also evaluated by endoscopy. The response to
chemotherapy was evaluated by CT scan, and by ultrasonography
and endoscopy when appropriate. In patients with measurable or
evaluable disease, response was evaluated using WHO response
criteria (WHO, 1979).
Statistical methods
Pretreatment characteristics that were analysed for prognostic
significance were age, sex, performance status, weight loss (o5, 5–
10, 410%), time from diagnosis to the start of chemotherapy,
histology (adenocarcinoma or squamous cell carcinoma), tumour
grade, haemoglobin, alkaline phosphatase, lactate dehydrogenase
(LDH), treatment with a dose-dense combination of cisplatin and
paclitaxel (studies 4–6) vs a combination of cisplatin, etoposide
with or without 5-fluorouracil (study 1,2,3), extent of disease and
response to treatment.
Patients with locally irresectable disease without metastases
were categorised as having locoregional disease, patients with
lymph node metastases confined to either the celiac or supracla-
vicular region as having limited disseminated disease and patients
with distant metastases or lymph node metastases in both celiac
and supraclavicular lymph nodes as having extensively dissemi-
nated disease.
Statistical analysis was performed using the SPSS software (SPSS
inc, Chicago, IL, USA). Survival was defined as the time elapsing
from the start of chemotherapy to death or to the date of last
follow-up. All survival data had been updated to August 2001.
Survival curves according to the putative prognostic factors were
drawn using the method of Kaplan and Meier (1958), and were
Table 1 Studies characteristics
Study Design (phase) Tumor type Patients no. Chemotherapy Schedule Reference
1 II SCC 73
9
=
;
Cisplatin 80mgm
 2 d1
Etoposide administered every 4 weeks 100mg d1,2 Kok et al (1996)
Etoposide 200mgm
 2 p.o. d3,5
2 II SCC 71
9
> > > > =
> > > > ;
Cisplatin 80mgm
 2 d1
Etoposide 125mgm
 2 d1
Etoposide administered every 4 weeks 200mgm
 2 p.o. d3,5 Polee et al (2001)
5-Fluorouracil 375mgm
 2 d1-4
Folinic acid 6 30mg p.o. d1-4
3 II Adenoca 68
9
> > > > =
> > > > ;
Cisplatin 80mgm
 2 d1
Etoposide 125mgm
 2 d1
Etoposide acid administered every 4 weeks 200mgm
 2 p.o. d3,5 Kok et al (1997)
5-fluorouracil 375mgm
 2 d1-4
Folinic acid 6 30mg p.o. d1-4
4 I SCC+adenoca 64
9
=
;
Cisplatin 60mgm
 2 d1
Paclitaxel administered every 2 weeks 100mgm
 2 d1 Van der Gaast et al (1999)
escalating to 200mgm
 2
5 I SCC+adenoca 24
9
=
;
Cisplatin 70mgm
 2 d1
Paclitaxel administered every week 80mgm
 2 - d1 Polee et al (2002b)
escalating to 110mgm
 2
6 II SCC+adenoca 51
 
Cisplatin administered every week 60mgm
 2 d1
Paclitaxel 180mgm
 2 d1 Polee et al (2002a)
SCC¼squamous cell carcinoma.
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were univariately significantly related to prognosis were further
evaluated in multivariate analyses. The Cox proportional hazards
model (Cox regression) was used with backward elimination to
find the most important independent prognostic factors (Cox,
1972). P¼0.05 (two-sided) was considered the limit of signifi-
cance. To circumvent difficulties with respect to the time bias
(Anderson et al, 1983), the association between tumour response
(partial or complete) and survival was assessed only in patients
who survived 4 months after the start of treatment. P¼0.05 (two-
sided) was considered the limit of significance.
RESULTS
A total of 351 patients were analysed. All patients received at least
one course of cisplatin-based combination chemotherapy. One
patient had no follow-up and was excluded from further analysis.
The characteristics of the remaining 350 patients are listed in
Table 2. Patients included in the database were all registered before
30 June 1999 and the date of reference for the survival analysis was
31 August 2001. At the time of this analysis, 27 patients were alive.
The median survival of all patients was 9 months (95% confidence
interval 8–10 months). The 1-, 2- and 5-year survival rates were
33, 12 and 4%, respectively.
Univariate analysis
Table 3 summarises the results of the univariate survival analyses.
Significant variables related to survival were: performance status,
weight loss, LDH, alkaline phosphatase, liver metastases, number
of metastatic sites, extent of disease and treatment with a dose-
dense cisplatin and paclitaxel chemotherapy regimen. Patients
with locoregional irresectable disease and patients with limited
disseminated disease had a significantly better survival than
patients with extensively disseminated disease.
Multivariate analysis
Multivariate analysis showed that good performance score, limited
disseminated disease, normal LDH and treatment with a dose-
dense schedule of cisplatin and paclitaxel were independent
prognostic factors (Table 4). WHO performance status and extent
of disease are the strongest predictors for survival. Lactate
dehydrogenase was a relevant risk factor, but was elevated in only
15% of patients. The type of treatment is an additional (external)
factor determining prognosis.
We combined the patient characteristics such as performance
status, extent of disease and LDH, to constitute four groups. A
WHO performance score of 2, extensive disseminated disease and
an elevated LDH were risk factors for poor survival, and the
survival of patients with either 0, 1, 2 or 3 risk factors present was
estimated. As shown in Figure 1, there is a large difference in
survival between these four patient groups. The median survivals
of patients with 0, 1, 2 and 3 risk factors were 12, 8, 6 and 4
months, respectively. The 1-year survival rates were 45, 30, 18 and
0%, respectively. In the group of patients with three risk factors, no
patient survived more than 9 months. Cox regression showed that
the type of treatment did not significantly influence the relative
differences in death rates between these four patient groups.
The relation between tumour response and survival was
evaluated in patients who survived 4 months. Of the responding
137 patients, the median survival was 15 months as compared to 8
months of the 146 nonresponders (Po0.001). Cox regression
showed that the response was a favourable prognostic factor,
independent of the type of treatment and number of risk factors
present. Adjusted for both these factors, the death rate among
responding patients was reduced by 70% (Po0.001).
The characteristics of the group of patients with a survival of
more than 3 years are listed in Table 5. The majority of these
patients had the following characteristics: a performance status 0
or 1, limited disease, partial or complete response to chemotherapy
and additional treatment after chemotherapy with either radio-
therapy or surgery. Out of 178 patients with locoregional disease or
limited lymph node metastases, 60 patients received additional
treatment, 31 patients received radiotherapy to a total dose of
50Gy and 29 patients underwent an oesophageal resection. In all,
17 of these 60 patients (28%) survived at least 3 years.
DISCUSSION
Knowledge of prognostic factors is essential for the management of
individual patients and these factors should be taken into account
in the design of randomised trails and in interpreting the results of
such trials.
In patients with resectable oesophageal cancer, survival
correlates closely with the extent of tumour infiltration in the
oesophageal wall and the presence or absence of lymph node
metastasis (Kato et al, 1993). Weight loss has also been identified
as an independent prognostic factor in patients who were
surgically treated with or without preoperative chemotherapy
(Kelsen et al, 1998). Performance status has been reported to be an
important prognostic factor in patients treated with radiotherapy
alone (Coia et al, 2000). In a number of studies, the prognostic
significance of biological factors such as oncogenes, tumour-
suppressor genes and growth factors has been studied. Over-
expression of p53, p21 and vascular endothelial growth factor has
been identified as prognostic factors by some authors (Ikeda et al,
1999; Shimada et al, 2000), but the results of these studies are not
always consistent and therefore these factors are currently not used
in daily routine. Prognostic factor analyses in patients with locally
Table 2 Patient characteristics (n¼350)
Characteristic No. of patients (%)
Sex
Male 278 79
Female 72 21
Age (years)
Median 56
Range 28–78
WHO performance status
06 6 1 9
1 219 63
26 3 1 8
Weight loss (%)
o5 121 35
5–10 91 26
410 131 37
Unknown 7 2
Histology
Adenocarcinoma 145 41
Squamous cell carcinoma 199 57
Undifferentiated carcinoma 6 2
Extent of disease
Locally advanced/unresectable 42 12
Limited disseminated disease
a 138 39
Extensive disseminated disease
b 170 49
aLymph node metastasis confined to either the celiac or supraclavicular region.
bDistant metastasis or lymph node metastasis in both celiac and supraclavicular lymph
nodes.
Prognostic factors for survival in patients with oesophageal cancer
MB Polee et al
2047
British Journal of Cancer (2003) 89(11), 2045–2050 & 2003 Cancer Research UK
C
l
i
n
i
c
a
ladvanced or metastatic oesophageal cancer treated with che-
motherapy are scarce. Andreyev et al (1998) identified weight loss
as an independent prognostic factor in patients with several
gastrointestinal malignancies, but weight loss was not statistically
significant in the subgroup of patients with advanced oesophageal
cancer.
In this study, we analysed prechemotherapy characteristics
in 350 patients with locally advanced or metastatic oesopha-
geal cancer, who were treated with cisplatin-based chemotherapy.
In multivariate analysis, performance status, extent of disease,
LDH and the addition of paclitaxel to cisplatin were identified as
the most important prognostic factors. Weight loss dropped out of
the multivariate model when performance status was also
included. This can be explained by the finding that most patients
with a poor performance status also had significant weight loss.
Metastatic involvement of the liver and the total number of
metastatic sites lost their importance when studied with disease
extent.
Based on the performance score, LDH and extent of disease, we
were able to identify four prognostic groups. The median survivals
of patients with zero, one, two and three risk factors were 12, 8, 6
Table 3 Univariate survival analysis
Characteristic Categories Patients(no) Survival median (months) 1-year (%) Logrank P
Age (years) o60 215 9 29 0.235
D60 135 11 39
Gender Female 72 11 42 0.390
Male 278 9 30
Performance status (WHO) 0 66 12 45 o0.001
a
1 219 10 35
26 3 5 1 3
Weight loss (%) O 5 121 12 39 0.006
a
5–10 91 9 32
D 10 131 9 29
Tumor type SCC 199 9 32 0.550
Adenoca 145 10 32
Tumor differentiation
b Well/moderate 119 10 43 0.102
Poor 131 9 28
Liver metastasis No 269 10 37 o0.001
Yes 81 7 21
No. of metastatic sites 0 42 10 36 0.02
a
1 190 10 34
41 118 7 31
Extent of disease Locoregional 42 10 36 o 0.001
c
Limited dissem. 138 12 41 o 0.001
c
Extensive dissem. 170 7 26
Interval between diagnosis and start treatment o6 months 295 10 34 0.65
46 months 55 8 27
Haemoglobin Normal 228 10 36 0.253
Abnormal 122 9 28
Alkaline phosphatase Normal 246 10 37 0.001
Elevated 104 7 24
LDH Normal 296 11 46 o0.001
Elevated 54 8 16
Paclitaxel Yes 139 10 40 0.002
No 211 9 29
aTrend test,
btumour differentiation was unknown in 100 patients,
cvs extended dissemination.
Table 4 Cox multivariate regression model
Characteristic RDR 95% CI RDR P
Performance
WHO 0 1
1 1.3 1.0–1,8 0.069
2 2.4 1.6–3.5 o0.001
Extent of disease
Locoregional 0.7 0.5–1.0 0.08
Limited dissemination 0.7 0.5–0.9 0.006
Extensive dissemination 1
LDH
Normal 1
Elevated 1.5 1.1–2.0 0.021
Paclitaxel
Yes 1
No 1.3 1.1–1.7 0.015
RDR¼relative death rate, CI¼confidence interval.
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land 4 months, respectively. Considering a median survival of 4
months for patients with three risk factors and the fact that none of
these patients survived beyond 9 months, it is unlikely that these
patients had any benefit from chemotherapy, at least with respect
to survival. Tumour response as a post-treatment factor was found
to be a favourable prognostic sign that was independent of the type
of treatment and the number of risk factors present. However, the
true merits of chemotherapy can only be assessed in randomised
trials incorporating the stratification for risk factors and the
measurement of quality of life.
Patients with lymph node metastases confined to either the
celiac or supraclavicular lymph nodes had a better survival than
patients with more extensive disease. The 3-year survival rate of
the 136 patients with lymph node metastasis only was 11%. Most of
the patients who survived more than 3 years after the start of
chemotherapy were additionally treated with surgery or radio-
therapy.
We found that patients treated in the more recent studies with
dose-dense schedules of cisplatin and paclitaxel had a significantly
better survival compared to patients treated with cisplatin and
etoposide with or without 5-fluorouracil. The dose-dense sche-
dules might bias the comparison of treatment schedules. Although
the total dose of cisplatin was more or less comparable to the dose,
the intensity (mgm
 2week
 1) was significantly higher in the
cisplatin and paclitaxel regimens. The improved outcome in the
latter studies can be due to either the addition of paclitaxel or to
the dose-dense character of these schedules.
In conclusion, performance score, extent of disease and LDH are
independent prognostic factors in patients with advanced oeso-
phageal cancer, who are treated with cisplatin-based combination
chemotherapy. Patients with a poor performance, extensive
disseminated disease and an elevated LDH have a poor outcome
and should not be treated with cisplatin-based combination
chemotherapy.
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